The majority of your experiments, participated in experimental design and style and interpretation

Материал из WikiSyktSU
Перейти к: навигация, поиск

The authors would like to thank Dr Stuart Williamson for supplying us with the prostate tissue lysates utilised in this study, and Dr Mirco Menigatti for Gentamicin (sulfate) cost kindly giving us using the PTPRR pcDNA3.1 plasmid. Author facts 1 Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne NE1 3BZ, UK. 2Cancer Investigation UK Beatson Institute, buy 500-42-5 Glasgow G61 1BD, UK. three Institute of Cancer Sciences, University of Glasgow, Glasgow G12 8QQ, UK. 4 Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK. Received: 27 Could 2014 Accepted: six JanuaryReferences 1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality prices. Eur Urol. 2012;61:1079?2. 2. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28250575 androgen receptor fuels PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26795252 prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719?3. three. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501?1. 4. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The androgen receptor induces a distinct transcriptional system in castration-resistant prostate cancer in man. Cancer Cell. 2013;23:35?7. 5. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer. 2014;14:187?eight. 6. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575?six. 7. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation on the tumor suppressor PTEN/MMAC1 in sophisticated human prostate cancer by means of loss of expression. Proc Natl Acad Sci U S A. 1998;95:5246?0. 8. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator in the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1998;95:15587?1. 9. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of your murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209?1. ten. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ. Activation of mitogen-activated protein kinase connected with prostate cancer progression. Cancer Res.The majority of your experiments, participated in experimental design and interpretation of final results, and drafted the manuscript. NPL assisted with some of the molecular experiments and was involved inside the conception of your study and also the interpretation of outcomes. GK and PR carried out the IPA pathway evaluation. CNR and HYL have been involved within the evaluation and interpretation of data, and were involved in critically revising the manuscript. DJE and PR conceived of your study, participated in its style and coordination and helped to draft the manuscript. All authors study and authorized the final manuscript.